Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBERTY: Erenumab in episodic migraine
NCT03096834Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2017
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of erenumab in episodic migraine, sponsored by Novartis. Started Mar 2017; status: completed.
02
Drugs
erenumab
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT03096834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03096834.